Xilio Therapeutics (XLO) Operating Expenses (2020 - 2026)

Xilio Therapeutics has disclosed Operating Expenses across 7 years of filings, most recently posting $26.8 million for Q1 2026.

• Operating Expenses for Q1 2026 came in at $26.8 million, up 59.47% year-over-year; the trailing twelve-month figure through Mar 2026 was $95.7 million (up 44.56% YoY), and the FY2025 annual result was $85.7 million, up 28.12% from the prior year.
• Operating Expenses came in at $26.8 million for Q1 2026 at Xilio Therapeutics, up from $25.5 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $26.8 million in Q1 2026 to a low of $15.4 million in Q4 2024.
• The 5-year median for Operating Expenses is $20.2 million (2022), against an average of $20.5 million.
• Across the five-year window, Operating Expenses decreased 25.67% in 2024 and soared 66.23% in 2025, its largest moves.
• Xilio Therapeutics' Operating Expenses stood at $23.2 million in 2022, then decreased by 21.74% to $18.1 million in 2023, then retreated by 15.32% to $15.4 million in 2024, then jumped by 66.23% to $25.5 million in 2025, then grew by 4.85% to $26.8 million in 2026.
• The last three Operating Expenses figures came in at $26.8 million (Q1 2026), $25.5 million (Q4 2025), and $21.0 million (Q3 2025), per Business Quant data.